Authors
María Fernanda González-Lara, Pedro Torres-González, Patricia Cornejo-Juárez, Consuelo Velázquez-Acosta, Areli Martinez-Gamboa, Andrea Rangel-Cordero, Miriam Bobadilla-del-Valle, Luis Ostrosky-Zeichner, Alfredo Ponce-de-León, José Sifuentes-Osornio
Publication date
2017/12
Journal
BMC Infectious Diseases
Volume
17
Pages
1-9
Publisher
BioMed Central
Description
Background
The mortality of Candida Bloodstream Infection (CBSI) remains high. Antifungal susceptibility breakpoints were recently updated for Candida species, the impact remains unknown. In this study we evaluated the impact of inappropriate antifungal treatment according to recent breakpoints on 30-day mortality of CBSI.
Methods
From June 2008 to July 2014, data on CBSI episodes from two tertiary-care centers, treated > 72 h were analyzed. Antifungal therapy and 30-day mortality were registered. Inappropriate antifungal treatment according to current Clinical & Laboratory Standards Institute (CLSI) breakpoints was adjusted with 30-day mortality-related co-variates.
Results
One hundred forty-nine episodes of CBSI were analyzed. The most frequent species were: C. albicans (40%), C. tropicalis (23%) and C …
Scholar articles
MF González-Lara, P Torres-González… - BMC Infectious Diseases, 2017